Lantern pharma announces abstract on effectiveness of lp-284 in hematologic cancers accepted for presentation at the 63rd american society of hematology (ash) annual meeting

Dallas, nov. 4, 2021 /prnewswire/ -- lantern pharma (nasdaq: ltrn), a clinical stage biopharmaceutical company using its proprietary radr® artificial intelligence ("a.i.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that lantern pharma's abstract on the effectiveness of lp-284 in hematologic cancers has been accepted as a poster at the upcoming 63rd american society of hematology (ash) annual meeting, which is being held in-person and virtually from december 11 – 14, 2021.
LTRN Ratings Summary
LTRN Quant Ranking